Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study

Susanne Roehr; Alexander Pabst; Steffi G. Riedel-Heller; Frank Jessen; Yuda Turana; Yvonne S. Handajani; Carol Brayne; Fiona E. Matthews; Blossom C. M. Stephan; Richard B. Lipton; Mindy J. Katz; Cuiling Wang; Maelenn Guerchet; Pierre-Marie Preux; Pascal Mbelesso; Karen Ritchie; Marie-Laure Ancelin; Isabelle Carriere; Antonio Guaita; Annalisa Davin; Roberta Vaccaro; Ki Woong Kim; Ji Won Han; Seung Wan Suh; Suzana Shahar; Normah C. Din; Divya Vanoh; Martin van Boxtel; Sebastian Koehler; Mary Ganguli; Erin P. Jacobsen; Beth E. Snitz; Kaarin J. Anstey; Nicolas Cherbuin; Shuzo Kumagai; Sanmei Chen; Kenji Narazaki; Tze Pin Ng; Qi Gao; Xinyi Gwee; Henry Brodaty; Nicole A. Kochan; Julian Trollor; Antonio Lobo; Raul Lopez-Anton; Javier Santabarbara; John D. Crawford; Darren M. Lipnicki; Perminder S. Sachdev; Cohort Studies of Memory in an International Consortium (COSMIC)

doi:10.1186/s13195-020-00734-y

Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study

Susanne Roehr^*, Alexander Pabst, Steffi G. Riedel-Heller, Frank Jessen, Yuda Turana, Yvonne S. Handajani, Carol Brayne, Fiona E. Matthews, Blossom C. M. Stephan, Richard B. Lipton, Mindy J. Katz, Cuiling Wang, Maelenn Guerchet, Pierre-Marie Preux, Pascal Mbelesso, Karen Ritchie, Marie-Laure Ancelin, Isabelle Carriere, Antonio Guaita, Annalisa DavinRoberta Vaccaro, Ki Woong Kim, Ji Won Han, Seung Wan Suh, Suzana Shahar, Normah C. Din, Divya Vanoh, Martin van Boxtel, Sebastian Koehler, Mary Ganguli, Erin P. Jacobsen, Beth E. Snitz, Kaarin J. Anstey, Nicolas Cherbuin, Shuzo Kumagai, Sanmei Chen, Kenji Narazaki, Tze Pin Ng, Qi Gao, Xinyi Gwee, Henry Brodaty, Nicole A. Kochan, Julian Trollor, Antonio Lobo, Raul Lopez-Anton, Javier Santabarbara, John D. Crawford, Darren M. Lipnicki, Perminder S. Sachdev, Cohort Studies of Memory in an International Consortium (COSMIC)

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background Subjective cognitive decline (SCD) is recognized as a risk stage for Alzheimer's disease (AD) and other dementias, but its prevalence is not well known. We aimed to use uniform criteria to better estimate SCD prevalence across international cohorts. Methods We combined individual participant data for 16 cohorts from 15 countries (members of the COSMIC consortium) and used qualitative and quantitative (Item Response Theory/IRT) harmonization techniques to estimate SCD prevalence. Results The sample comprised 39,387 cognitively unimpaired individuals above age 60. The prevalence of SCD across studies was around one quarter with both qualitative harmonization/QH (23.8%, 95%CI = 23.3-24.4%) and IRT (25.6%, 95%CI = 25.1-26.1%); however, prevalence estimates varied largely between studies (QH 6.1%, 95%CI = 5.1-7.0%, to 52.7%, 95%CI = 47.4-58.0%; IRT: 7.8%, 95%CI = 6.8-8.9%, to 52.7%, 95%CI = 47.4-58.0%). Across studies, SCD prevalence was higher in men than women, in lower levels of education, in Asian and Black African people compared to White people, in lower- and middle-income countries compared to high-income countries, and in studies conducted in later decades. Conclusions SCD is frequent in old age. Having a quarter of older individuals with SCD warrants further investigation of its significance, as a risk stage for AD and other dementias, and of ways to help individuals with SCD who seek medical advice. Moreover, a standardized instrument to measure SCD is needed to overcome the measurement variability currently dominant in the field.

Original language	English
Article number	167
Number of pages	14
Journal	Alzheimers research & therapy
Volume	12
Issue number	1
DOIs	https://doi.org/10.1186/s13195-020-00734-y
Publication status	Published - 18 Dec 2020

Keywords

Subjective cognitive decline
Prevalence
Epidemiology
Individual participant data
Data harmonization
Cohort study
MINI-MENTAL-STATE
MEMORY COMPLAINTS
DEMENTIA
DETERIORATION
PERFORMANCE
COMMUNITY
FRAMEWORK
CRITERIA
PEOPLE
HEALTH

Access to Document

10.1186/s13195-020-00734-yLicence: CC BY

Cite this

Roehr, S., Pabst, A., Riedel-Heller, S. G., Jessen, F., Turana, Y., Handajani, Y. S., Brayne, C., Matthews, F. E., Stephan, B. C. M., Lipton, R. B., Katz, M. J., Wang, C., Guerchet, M., Preux, P.-M., Mbelesso, P., Ritchie, K., Ancelin, M.-L., Carriere, I., Guaita, A., ... Cohort Studies of Memory in an International Consortium (COSMIC) (2020). Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study. Alzheimers research & therapy, 12(1), Article 167. https://doi.org/10.1186/s13195-020-00734-y

@article{3b1806b0e3fc47bf867a1bf77631d7bf,

title = "Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study",

abstract = "Background Subjective cognitive decline (SCD) is recognized as a risk stage for Alzheimer's disease (AD) and other dementias, but its prevalence is not well known. We aimed to use uniform criteria to better estimate SCD prevalence across international cohorts. Methods We combined individual participant data for 16 cohorts from 15 countries (members of the COSMIC consortium) and used qualitative and quantitative (Item Response Theory/IRT) harmonization techniques to estimate SCD prevalence. Results The sample comprised 39,387 cognitively unimpaired individuals above age 60. The prevalence of SCD across studies was around one quarter with both qualitative harmonization/QH (23.8%, 95%CI = 23.3-24.4%) and IRT (25.6%, 95%CI = 25.1-26.1%); however, prevalence estimates varied largely between studies (QH 6.1%, 95%CI = 5.1-7.0%, to 52.7%, 95%CI = 47.4-58.0%; IRT: 7.8%, 95%CI = 6.8-8.9%, to 52.7%, 95%CI = 47.4-58.0%). Across studies, SCD prevalence was higher in men than women, in lower levels of education, in Asian and Black African people compared to White people, in lower- and middle-income countries compared to high-income countries, and in studies conducted in later decades. Conclusions SCD is frequent in old age. Having a quarter of older individuals with SCD warrants further investigation of its significance, as a risk stage for AD and other dementias, and of ways to help individuals with SCD who seek medical advice. Moreover, a standardized instrument to measure SCD is needed to overcome the measurement variability currently dominant in the field.",

keywords = "Subjective cognitive decline, Prevalence, Epidemiology, Individual participant data, Data harmonization, Cohort study, MINI-MENTAL-STATE, MEMORY COMPLAINTS, DEMENTIA, DETERIORATION, PERFORMANCE, COMMUNITY, FRAMEWORK, CRITERIA, PEOPLE, HEALTH",

author = "Susanne Roehr and Alexander Pabst and Riedel-Heller, {Steffi G.} and Frank Jessen and Yuda Turana and Handajani, {Yvonne S.} and Carol Brayne and Matthews, {Fiona E.} and Stephan, {Blossom C. M.} and Lipton, {Richard B.} and Katz, {Mindy J.} and Cuiling Wang and Maelenn Guerchet and Pierre-Marie Preux and Pascal Mbelesso and Karen Ritchie and Marie-Laure Ancelin and Isabelle Carriere and Antonio Guaita and Annalisa Davin and Roberta Vaccaro and Kim, {Ki Woong} and Han, {Ji Won} and Suh, {Seung Wan} and Suzana Shahar and Din, {Normah C.} and Divya Vanoh and {van Boxtel}, Martin and Sebastian Koehler and Mary Ganguli and Jacobsen, {Erin P.} and Snitz, {Beth E.} and Anstey, {Kaarin J.} and Nicolas Cherbuin and Shuzo Kumagai and Sanmei Chen and Kenji Narazaki and Ng, {Tze Pin} and Qi Gao and Xinyi Gwee and Henry Brodaty and Kochan, {Nicole A.} and Julian Trollor and Antonio Lobo and Raul Lopez-Anton and Javier Santabarbara and Crawford, {John D.} and Lipnicki, {Darren M.} and Sachdev, {Perminder S.} and {Cohort Studies of Memory in an International Consortium (COSMIC)}",

note = "Funding Information: Susanne R{\"o}hr was supported by the LIFE—Leipzig Research Center for Civilization Diseases, University of Leipzig, funded by the European Social Fund and the Free State of Saxony (grant number LIFE-103 P1). This work was further supported by a grant from the Hans and Ilse Breuer Foundation. Funding for COSMIC comes from a National Health and Medical Research Council of Australia Program Grant (ID 1093083) (PSS, HB), the National Institute On Aging of the National Institutes of Health under Award Number RF1AG057531 (PSS, MG, RBL, KR, KWK, HB), and philanthropic contributions to The Dementia Momentum Fund (UNSW Project ID PS38235). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funders. Funding for each of the contributing studies is as follows: ActiveAging: no funding; CFAS: major awards from the Medical Research Council and the Department of Health, UK; EAS: Supported in part by National Institutes of Health grants NIA 2 P01 AG03949, the Leonard and Sylvia Marx Foundation, and the Czap Foundation; EPIDEMCA: French National Research Agency (ANR-09-MNPS-009-01); ESPRIT: Novartis; Invece.Ab: Financed with own funds and supported in part by “Federazione Alzheimer Italia”, Milan, Italy (AG); KLOSCAD: the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [Grant No. HI09C1379 (A092077)]; LEILA75+: the Interdisciplinary Centre for Clinical Research at the University of Leipzig (Interdisziplin{\"a}res Zentrum f{\"u}r Klinische Forschung/IZKF; grant 01KS9504); LRGS-TUA: Ministry of Education Longterm Research Grant Scheme (LRGS/BU/2012/UKM–UKM/K/01); MAAS: The Netherlands Organization for Scientific Research (NOW). Grant Number: 002.005.019; MoVIES: Grant # R01AG07562 from the National Institute on Aging, National Institutes of Health, United States Department of Health and Human Services; PATH: National Health and Medical Research Council of Australia grants 973302, 179805, 157125, and 1002160; SGS: JSPS KAKENHI Grant Number JP17K09146; SLASII: The SLASII study was supported by research grants from the Agency for Science Technology and Research (A*STAR) Biomedical Research Council (BMRC) https://www.a-star.edu.sg/ [Grants 03/1/21/17/214 and 08/1/21/19/567] and the National Medical Research Council http://www.nmrc.gov.sg/ [Grant: NMRC/1108/2007]; ZARADEMP: Supported by grants from the Fondo de Investigaci{\'o}n Sanitaria, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness, Madrid, Spain (grants 94/1562, 97/1321E, 98/0103, 01/0255, 03/0815, 06/0617, G03/128), and the Fondo Europeo de Desarrollo Regional (FEDER) of the European Union and Gobierno de Arag{\'o}n, Group #19. Open Access funding enabled and organized by Projekt DEAL. Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = dec,

day = "18",

doi = "10.1186/s13195-020-00734-y",

language = "English",

volume = "12",

journal = "Alzheimers research & therapy",

publisher = "BioMed Central Ltd",

number = "1",

}

Roehr, S, Pabst, A, Riedel-Heller, SG, Jessen, F, Turana, Y, Handajani, YS, Brayne, C, Matthews, FE, Stephan, BCM, Lipton, RB, Katz, MJ, Wang, C, Guerchet, M, Preux, P-M, Mbelesso, P, Ritchie, K, Ancelin, M-L, Carriere, I, Guaita, A, Davin, A, Vaccaro, R, Kim, KW, Han, JW, Suh, SW, Shahar, S, Din, NC, Vanoh, D, van Boxtel, M , Koehler, S, Ganguli, M, Jacobsen, EP, Snitz, BE, Anstey, KJ, Cherbuin, N, Kumagai, S, Chen, S, Narazaki, K, Ng, TP, Gao, Q, Gwee, X, Brodaty, H, Kochan, NA, Trollor, J, Lobo, A, Lopez-Anton, R, Santabarbara, J, Crawford, JD, Lipnicki, DM, Sachdev, PS & Cohort Studies of Memory in an International Consortium (COSMIC) 2020, 'Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging: a COSMIC study', Alzheimers research & therapy, vol. 12, no. 1, 167. https://doi.org/10.1186/s13195-020-00734-y

TY - JOUR

T1 - Estimating prevalence of subjective cognitive decline in and across international cohort studies of aging

T2 - a COSMIC study

AU - Roehr, Susanne

AU - Pabst, Alexander

AU - Riedel-Heller, Steffi G.

AU - Jessen, Frank

AU - Turana, Yuda

AU - Handajani, Yvonne S.

AU - Brayne, Carol

AU - Matthews, Fiona E.

AU - Stephan, Blossom C. M.

AU - Lipton, Richard B.

AU - Katz, Mindy J.

AU - Wang, Cuiling

AU - Guerchet, Maelenn

AU - Preux, Pierre-Marie

AU - Mbelesso, Pascal

AU - Ritchie, Karen

AU - Ancelin, Marie-Laure

AU - Carriere, Isabelle

AU - Guaita, Antonio

AU - Davin, Annalisa

AU - Vaccaro, Roberta

AU - Kim, Ki Woong

AU - Han, Ji Won

AU - Suh, Seung Wan

AU - Shahar, Suzana

AU - Din, Normah C.

AU - Vanoh, Divya

AU - van Boxtel, Martin

AU - Koehler, Sebastian

AU - Ganguli, Mary

AU - Jacobsen, Erin P.

AU - Snitz, Beth E.

AU - Anstey, Kaarin J.

AU - Cherbuin, Nicolas

AU - Kumagai, Shuzo

AU - Chen, Sanmei

AU - Narazaki, Kenji

AU - Ng, Tze Pin

AU - Gao, Qi

AU - Gwee, Xinyi

AU - Brodaty, Henry

AU - Kochan, Nicole A.

AU - Trollor, Julian

AU - Lobo, Antonio

AU - Lopez-Anton, Raul

AU - Santabarbara, Javier

AU - Crawford, John D.

AU - Lipnicki, Darren M.

AU - Sachdev, Perminder S.

AU - Cohort Studies of Memory in an International Consortium (COSMIC)

N1 - Funding Information: Susanne Röhr was supported by the LIFE—Leipzig Research Center for Civilization Diseases, University of Leipzig, funded by the European Social Fund and the Free State of Saxony (grant number LIFE-103 P1). This work was further supported by a grant from the Hans and Ilse Breuer Foundation. Funding for COSMIC comes from a National Health and Medical Research Council of Australia Program Grant (ID 1093083) (PSS, HB), the National Institute On Aging of the National Institutes of Health under Award Number RF1AG057531 (PSS, MG, RBL, KR, KWK, HB), and philanthropic contributions to The Dementia Momentum Fund (UNSW Project ID PS38235). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funders. Funding for each of the contributing studies is as follows: ActiveAging: no funding; CFAS: major awards from the Medical Research Council and the Department of Health, UK; EAS: Supported in part by National Institutes of Health grants NIA 2 P01 AG03949, the Leonard and Sylvia Marx Foundation, and the Czap Foundation; EPIDEMCA: French National Research Agency (ANR-09-MNPS-009-01); ESPRIT: Novartis; Invece.Ab: Financed with own funds and supported in part by “Federazione Alzheimer Italia”, Milan, Italy (AG); KLOSCAD: the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [Grant No. HI09C1379 (A092077)]; LEILA75+: the Interdisciplinary Centre for Clinical Research at the University of Leipzig (Interdisziplinäres Zentrum für Klinische Forschung/IZKF; grant 01KS9504); LRGS-TUA: Ministry of Education Longterm Research Grant Scheme (LRGS/BU/2012/UKM–UKM/K/01); MAAS: The Netherlands Organization for Scientific Research (NOW). Grant Number: 002.005.019; MoVIES: Grant # R01AG07562 from the National Institute on Aging, National Institutes of Health, United States Department of Health and Human Services; PATH: National Health and Medical Research Council of Australia grants 973302, 179805, 157125, and 1002160; SGS: JSPS KAKENHI Grant Number JP17K09146; SLASII: The SLASII study was supported by research grants from the Agency for Science Technology and Research (A*STAR) Biomedical Research Council (BMRC) https://www.a-star.edu.sg/ [Grants 03/1/21/17/214 and 08/1/21/19/567] and the National Medical Research Council http://www.nmrc.gov.sg/ [Grant: NMRC/1108/2007]; ZARADEMP: Supported by grants from the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness, Madrid, Spain (grants 94/1562, 97/1321E, 98/0103, 01/0255, 03/0815, 06/0617, G03/128), and the Fondo Europeo de Desarrollo Regional (FEDER) of the European Union and Gobierno de Aragón, Group #19. Open Access funding enabled and organized by Projekt DEAL. Publisher Copyright: © 2020, The Author(s).

PY - 2020/12/18

Y1 - 2020/12/18

N2 - Background Subjective cognitive decline (SCD) is recognized as a risk stage for Alzheimer's disease (AD) and other dementias, but its prevalence is not well known. We aimed to use uniform criteria to better estimate SCD prevalence across international cohorts. Methods We combined individual participant data for 16 cohorts from 15 countries (members of the COSMIC consortium) and used qualitative and quantitative (Item Response Theory/IRT) harmonization techniques to estimate SCD prevalence. Results The sample comprised 39,387 cognitively unimpaired individuals above age 60. The prevalence of SCD across studies was around one quarter with both qualitative harmonization/QH (23.8%, 95%CI = 23.3-24.4%) and IRT (25.6%, 95%CI = 25.1-26.1%); however, prevalence estimates varied largely between studies (QH 6.1%, 95%CI = 5.1-7.0%, to 52.7%, 95%CI = 47.4-58.0%; IRT: 7.8%, 95%CI = 6.8-8.9%, to 52.7%, 95%CI = 47.4-58.0%). Across studies, SCD prevalence was higher in men than women, in lower levels of education, in Asian and Black African people compared to White people, in lower- and middle-income countries compared to high-income countries, and in studies conducted in later decades. Conclusions SCD is frequent in old age. Having a quarter of older individuals with SCD warrants further investigation of its significance, as a risk stage for AD and other dementias, and of ways to help individuals with SCD who seek medical advice. Moreover, a standardized instrument to measure SCD is needed to overcome the measurement variability currently dominant in the field.

AB - Background Subjective cognitive decline (SCD) is recognized as a risk stage for Alzheimer's disease (AD) and other dementias, but its prevalence is not well known. We aimed to use uniform criteria to better estimate SCD prevalence across international cohorts. Methods We combined individual participant data for 16 cohorts from 15 countries (members of the COSMIC consortium) and used qualitative and quantitative (Item Response Theory/IRT) harmonization techniques to estimate SCD prevalence. Results The sample comprised 39,387 cognitively unimpaired individuals above age 60. The prevalence of SCD across studies was around one quarter with both qualitative harmonization/QH (23.8%, 95%CI = 23.3-24.4%) and IRT (25.6%, 95%CI = 25.1-26.1%); however, prevalence estimates varied largely between studies (QH 6.1%, 95%CI = 5.1-7.0%, to 52.7%, 95%CI = 47.4-58.0%; IRT: 7.8%, 95%CI = 6.8-8.9%, to 52.7%, 95%CI = 47.4-58.0%). Across studies, SCD prevalence was higher in men than women, in lower levels of education, in Asian and Black African people compared to White people, in lower- and middle-income countries compared to high-income countries, and in studies conducted in later decades. Conclusions SCD is frequent in old age. Having a quarter of older individuals with SCD warrants further investigation of its significance, as a risk stage for AD and other dementias, and of ways to help individuals with SCD who seek medical advice. Moreover, a standardized instrument to measure SCD is needed to overcome the measurement variability currently dominant in the field.

KW - Subjective cognitive decline

KW - Prevalence

KW - Epidemiology

KW - Individual participant data

KW - Data harmonization

KW - Cohort study

KW - MINI-MENTAL-STATE

KW - MEMORY COMPLAINTS

KW - DEMENTIA

KW - DETERIORATION

KW - PERFORMANCE

KW - COMMUNITY

KW - FRAMEWORK

KW - CRITERIA

KW - PEOPLE

KW - HEALTH

U2 - 10.1186/s13195-020-00734-y

DO - 10.1186/s13195-020-00734-y

M3 - Article

C2 - 33339532

VL - 12

JO - Alzheimers research & therapy

JF - Alzheimers research & therapy

IS - 1

M1 - 167

ER -